Zimberelimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Zimberelimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Zimberelimab can convert its Monoclonal antibody profile and PD-1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Zimberelimab (query alias: Zimberelimab) |
|---|---|
| Modality / target | Monoclonal antibody; PD-1; PD-1 inhibitors |
| Highest global status | Approved |
| Originator | Harbin Gloria Pharmaceuticals Co., Ltd. |
| Active developers | Gilead Sciences, Inc., Arcus Biosciences, Inc., Taiho Pharmaceutical Co., Ltd. |
The MCP disease footprint includes PD-L1 positive Uterine Cervical Cancer, Hodgkin's Lymphoma, Advanced biliary tract cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07710885 | Phase 3 | Recruiting | 784 | Overall Survival (OS) |
| JPRN-jRCT2051260023 | Phase 2 | 募集中 | 103 | Objective response rate by independent review |
| NCT07424664 | Phase 2 | Recruiting | 30 | The objective response rate of the treatment |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
STAR-221: A phase III study of first-line (1L) domvanalimab (D), zimberelimab (Z), and chemotherapy (chemo) vs nivolumab (N) + chemo in advanced HER2-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJC/EAC)
Phase 3; n=1040; evaluation: Negative. Reported fields: mOS = 14.7 month ( 13.4 - 17.1); mOS = 17.2 month ( 13.3 - 19.9); mOS = 14.7 month ( 12.3 - 16.9)
A phase 1 study of futibatinib in combination with zimberelimab and chemotherapy in first-line unresectable advanced or metastatic biliary tract cancer
Phase 1; n=43; evaluation: Positive. Reported fields: DLT = NR
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Phase 2; n=193; evaluation: not stated. Reported fields: -; -; Safety Run-in Cohorts 1 and 2: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 = 0 percentage of participants
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Zimberelimab addresses PD-L1 positive Uterine Cervical Cancer, Hodgkin's Lymphoma, Advanced biliary tract cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-07-21 | 誉衡生物与华大吉诺因达成全方位战略合作协议 | Approved | Financial terms not disclosed |
| 2020-12-09 | Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer | Not disclosed | Financial terms not disclosed |
| 2020-05-27 | Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies | Phase 2 | US$175.0M upfront; US$1,600.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
